Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

36.12 +1.52 (+4.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For November 29, 2023
Companies Reporting Before The Bell • CollPlant Biotechnologies (NASDAQ:CLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million. 
Via Benzinga
Earnings Outlook For Arrowhead Pharma
 
Via Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Arrowhead Pharma's Future
 
Via Benzinga
Analyst Ratings for Arrowhead Pharma
 
Via Benzinga
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Arrowhead Pharma's Future
 
Via Benzinga
Expert Ratings for Arrowhead Pharma
 
Via Benzinga
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have  
Via Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
 
Via Benzinga
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time, 
Via Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
 
Via Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A. 
Via Investor's Business Daily
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS